Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017

A position statement of the Korean Diabetes Association

on behalf of the Committee of Clinical Practice Guideline of Korean Diabetes Association

Research output: Contribution to journalReview articleResearchpeer-review

13 Citations (Scopus)

Abstract

In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.

Original languageEnglish
Pages (from-to)337-348
Number of pages12
JournalDiabetes and Metabolism Journal
Volume41
Issue number5
DOIs
StatePublished - 1 Oct 2017

Fingerprint

Hypoglycemic Agents
Type 2 Diabetes Mellitus
Sodium-Glucose Transport Proteins
Clinical Trials
Dipeptidyl-Peptidase IV Inhibitors
Therapeutics
Thiazolidinediones
Practice Guidelines

Keywords

  • Diabetes mellitus
  • Hypoglycemic agents
  • Insulin
  • Practice guideline
  • Type 2

Cite this

on behalf of the Committee of Clinical Practice Guideline of Korean Diabetes Association. / Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017 : A position statement of the Korean Diabetes Association. In: Diabetes and Metabolism Journal. 2017 ; Vol. 41, No. 5. pp. 337-348.
@article{046c237eb5064727a5ccabfecee6dbc3,
title = "Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: A position statement of the Korean Diabetes Association",
abstract = "In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.",
keywords = "Diabetes mellitus, Hypoglycemic agents, Insulin, Practice guideline, Type 2",
author = "{on behalf of the Committee of Clinical Practice Guideline of Korean Diabetes Association} and Ko, {Seung Hyun} and Hur, {Kyu Yeon} and Rhee, {Sang Youl} and Kim, {Nan Hee} and Moon, {Min Kyong} and Park, {Seok O.} and Lee, {Byung Wan} and Kim, {Hyun Jin} and Choi, {Kyung Mook} and Kim, {Jin Hwa} and Kim, {Tae Nyun} and Lee, {Yong ho} and Kim, {Jin Hwa} and Hong, {Eun Gyoung} and Jaetaek Kim and Lee, {Won Young} and Bokrye Song and Kim, {Ji Young} and Yang, {Dong Hee} and Taeyoung Yang and Hyeongjin Kim",
year = "2017",
month = "10",
day = "1",
doi = "10.4093/dmj.2017.41.5.337",
language = "English",
volume = "41",
pages = "337--348",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "5",

}

Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017 : A position statement of the Korean Diabetes Association. / on behalf of the Committee of Clinical Practice Guideline of Korean Diabetes Association.

In: Diabetes and Metabolism Journal, Vol. 41, No. 5, 01.10.2017, p. 337-348.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017

T2 - A position statement of the Korean Diabetes Association

AU - on behalf of the Committee of Clinical Practice Guideline of Korean Diabetes Association

AU - Ko, Seung Hyun

AU - Hur, Kyu Yeon

AU - Rhee, Sang Youl

AU - Kim, Nan Hee

AU - Moon, Min Kyong

AU - Park, Seok O.

AU - Lee, Byung Wan

AU - Kim, Hyun Jin

AU - Choi, Kyung Mook

AU - Kim, Jin Hwa

AU - Kim, Tae Nyun

AU - Lee, Yong ho

AU - Kim, Jin Hwa

AU - Hong, Eun Gyoung

AU - Kim, Jaetaek

AU - Lee, Won Young

AU - Song, Bokrye

AU - Kim, Ji Young

AU - Yang, Dong Hee

AU - Yang, Taeyoung

AU - Kim, Hyeongjin

PY - 2017/10/1

Y1 - 2017/10/1

N2 - In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.

AB - In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.

KW - Diabetes mellitus

KW - Hypoglycemic agents

KW - Insulin

KW - Practice guideline

KW - Type 2

UR - http://www.scopus.com/inward/record.url?scp=85032575566&partnerID=8YFLogxK

U2 - 10.4093/dmj.2017.41.5.337

DO - 10.4093/dmj.2017.41.5.337

M3 - Review article

VL - 41

SP - 337

EP - 348

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 5

ER -